Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 5/20 | 0.42 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21065450 | 1.00 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL21128448 | 0.94 | MAPT (0.44) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL30271653 | 0.94 | MAPT (0.44) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL21065452 | 0.93 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL9119169 | 0.81 | MAPT (0.44) | MAPTALDH1A1KDM4EPOLBHPGD | |
| SCHEMBL9119173 | 0.81 | MAPT (0.44) | MAPTALDH1A1KDM4EPOLBHPGD | |
| SCHEMBL8987310 | 0.78 | MAPT (0.56) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL8987305 | 0.78 | MAPT (0.56) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL21065472 | 0.77 | KDM4E (0.51) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL21065456 | 0.77 | KDM4E (0.51) | MAPTALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11596626-B2 | Compound for use against pathogenic Neisseria and Haemophilus species and Moraxella catarrhalis | Universität Konstanz (DE) | 2023-03-07 | — | — | US | disclosed |
| US-20210169869-A1 | Compound for Use Against Pathogenic Neisseria and Haemophilus Species and Moraxella Catarrhalis | Universität Wien (AT) | 2021-06-10 | — | — | US | disclosed |
| EP-3728193-A1 | COMPOUND FOR USE AGAINST PATHOGENIC NEISSERIA AND HAEMOPHILUS SPECIES AND MORAXELLA CATARRHALIS | Universität Konstanz (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3502095-A1 | COMPOUND FOR USE AGAINST PATHOGENIC NEISSERIA AND HAEMOPHILUS SPECIES AND MORAXELLA CATARRHALIS | Universität Konstanz (DE) | 2019-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596626-B2 | Compound for use against pathogenic Neisseria and Haemophilus species and Moraxella catarrhalis | MLEC, MPO, B3GNT2 | MAPT 1211/4885ALDH1A1 1459/4885MEN1 121/4885 |
| US-20210169869-A1 | Compound for Use Against Pathogenic Neisseria and Haemophilus Species and Moraxella Catarrhalis | MLEC, MPO, B3GNT2 | MAPT 1211/4885ALDH1A1 1459/4885MEN1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.